



## **CHF Solutions, Inc. Enhances Commercial Team with the Establishment of a Field Clinical Organization and New Sales Territories**

February 22, 2018

EDEN PRAIRIE, Minn., Feb. 22, 2018 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS), today announces it has expanded its commercial operations team with the addition of three new field clinical specialists to help optimize use of its Aquadex FlexFlow System within its existing and future customer base. This addition brings the size of the field clinical team to five.

The field clinical team will enhance sales operations by working with doctors and nurses to optimize the use of the company's Aquadex FlexFlow device in patients suffering from fluid overload who have failed diuretic therapy. The company's clinical specialists will be based out of New York City, Cleveland, Ohio, Tampa, Fla., Charlotte, N.C. and Chicago, Ill., and will support the field sales staff nationwide. The company has also hired three field sales representatives for its existing Ohio and Texas territories and newly created Southeast territory.

"The hiring and deployment of these clinical specialists is an important step in our commercial strategy, as it allows us to provide clinical instruction and training to existing and new customers alike," said John Erb, president and CEO of CHF Solutions. "Ultrafiltration is an important alternative treatment for patients with fluid overload who have failed diuretic therapy. We are dedicated to educating and supporting doctors and nurses to optimize Aquadex utilization for patients who need different treatment options. Our clinical specialists will be instrumental in serving this mission."

### **About CHF Solutions**

CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.

### **Forward-Looking Statements**

Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, the statement regarding the field clinical team enhancing sales operations by working with doctors and nurses to optimize the use of the company's FlexFlow device. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our recently announced strategic realignment, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

### **CONTACTS:**

#### **INVESTORS:**

Claudia Napal Drayton  
Chief Financial Officer  
CHF Solutions, Inc.  
952-345-4205  
[ir@chf-solutions.com](mailto:ir@chf-solutions.com)

-or-

Bret Shapiro  
Managing Partner  
CORE IR  
516-222-2560  
[brets@coreir.com](mailto:brets@coreir.com)  
[www.coreir.com](http://www.coreir.com)

#### **MEDIA**

Jules Abraham  
JQA Partners, Inc.  
917-885-7378  
[jabraham@jqapartners.com](mailto:jabraham@jqapartners.com)

[Primary Logo](#)

Source: CHF Solutions, Inc.